Entos' Fusogenix PLV technology is ideal for the delivery of next generation nucleic acid-based therapies.
Unlike conventional lipid-based delivery systems, Fusogenix PLVs are well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique PLV formulations to effectively deliver a wide range of nucleic acid therapies, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.
Fusogenix PLVs are widely biodistributed across all organs and tissues.
Due to the unique biophysical and chemical properties of Fusogenix PLVs, a wide variety of extra-hepatic tissues can be effectively targeted at therapeutic doses. Entos has developed a panel of Fusogenix PLV formulations to accurately target specific tissues.
The Fusogenix PLV platform uses a novel fusion mechanism to deliver the payload directly inside cells.
Our proprietary FAST (Fusion-Associated Small Transmembrane) protein technology enables fusion of the proteo-lipid vehicle with the plasma membrane of target cells. Nucleic acid payloads are delivered intact into the cytoplasm for immediate use as a therapeutic agent.